The burden of viral hepatitides in the Russian Federation and ways of its reduction for the long term (in case of hepatitis C)

Yushchuk N.D.; Znoiko O.O.; Iakushechkina N.A.; Zyrianov S.K.; Shut’ko S.A.; Belyĭ P.A.; Kozina A.N.; Chapurin S.A.; Churilin Iu.Iu.; Lugovskikh E.A.

doi:https://doi.org/

Yushchuk N.D.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Znoiko O.O.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Iakushechkina N.A.

Kafedra infektsionnykh bolezneĭ i épidemiologii MGMSU im. A.I. Evdokimova Minzdrava Rossii;
kafedra klinicheskoĭ farmakologii lechebnogo fakul'teta RNIMU im. N.I. Pirogova, Moskva

Zyrianov S.K.

Kafedra klinicheskoĭ farmakologii LF Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova

Shut’ko S.A.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Belyĭ P.A.

Kafedra infektsionnykh bolezneĭ i épidemiologii MGMSU im. A.I. Evdokimova Minzdrava Rossii;
kafedra klinicheskoĭ farmakologii lechebnogo fakul'teta RNIMU im. N.I. Pirogova, Moskva

Kozina A.N.

Kafedra infektsionnykh bolezneĭ i épidemiologii MGMSU im. A.I. Evdokimova Minzdrava Rossii;
kafedra klinicheskoĭ farmakologii lechebnogo fakul'teta RNIMU im. N.I. Pirogova, Moskva

Chapurin S.A.

Moskovskiĭ NII psikhiatrii;
psikhonevrologicheskiĭ dispanser #13, Moskva

Churilin Iu.Iu.

Moskovskiĭ NII psikhiatrii;
psikhonevrologicheskiĭ dispanser #13, Moskva

Lugovskikh E.A.

Kafedra infektsionnykh bolezneĭ i épidemiologii MGMSU im. A.I. Evdokimova Minzdrava Rossii;
kafedra klinicheskoĭ farmakologii lechebnogo fakul'teta RNIMU im. N.I. Pirogova, Moskva

The burden of viral hepatitides in the Russian Federation and ways of its reduction for the long term (in case of hepatitis C)

Authors:

Yushchuk N.D., Znoiko O.O., Iakushechkina N.A., Zyrianov S.K., Shut’ko S.A., Belyĭ P.A., Kozina A.N., Chapurin S.A., Churilin Iu.Iu., Lugovskikh E.A.

More about the authors

Journal: Therapeutic Archive. 2013;85(12): 79‑85

Read: 752 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Yushchuk ND, Znoiko OO, Iakushechkina NA, et al. . The burden of viral hepatitides in the Russian Federation and ways of its reduction for the long term (in case of hepatitis C). Therapeutic Archive. 2013;85(12):79‑85. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Clinical and economic analysis of nutritional support in the perioperative treatment of lung cancer. P.A. Herzen Journal of Oncology. 2025;(5):54-58

Abstract:

Aim. To evaluate the impact of using the innovative antiviral drugs in patients with chronic hepatitis C (CHC) on the disease burden in the long term. Materials and methods. A program was developed to increase the availability of innovative antiviral therapy (AVT) in patients with CHC covering the period from 2013 to 2020. To evaluate the impact of the program on the burden of hepatitis C (HC) in the Russian Federation, a Markov model of the disease progression was developed till 2030. Calculations were made in medical and social perspectives. Results. The implementation of the program will allow to decrease the medical costs by RBL 2 billion and budget costs, including disability payments, by RBL 3.8 billion by 2030. During this period, in GDP losses will decrease by RBL 1.1 trillion and the total burden of HC taking into account the cost of the program by RBL 1 trillion. Conclusion. For the first time it was shown that the expanding coverage of CHC patients with innovative AVT will allow to reduce the costs of health and social services.

Keywords:

hepatitis C

burden

pharmacoeconomic analysis

antiviral therapy

telaprevir

pegylated interferons

Authors:

Yushchuk N.D.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Znoiko O.O.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Iakushechkina N.A.

Kafedra infektsionnykh bolezneĭ i épidemiologii MGMSU im. A.I. Evdokimova Minzdrava Rossii;
kafedra klinicheskoĭ farmakologii lechebnogo fakul'teta RNIMU im. N.I. Pirogova, Moskva

Zyrianov S.K.

Kafedra klinicheskoĭ farmakologii LF Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova

Shut’ko S.A.

State Budgetary EeducationalInstitution of Higher Professional Education «A.I. Evdokimov Moscow State Medical Stomatological University», Russian Ministry of Health

Belyĭ P.A.

Kafedra infektsionnykh bolezneĭ i épidemiologii MGMSU im. A.I. Evdokimova Minzdrava Rossii;
kafedra klinicheskoĭ farmakologii lechebnogo fakul'teta RNIMU im. N.I. Pirogova, Moskva

Kozina A.N.

Kafedra infektsionnykh bolezneĭ i épidemiologii MGMSU im. A.I. Evdokimova Minzdrava Rossii;
kafedra klinicheskoĭ farmakologii lechebnogo fakul'teta RNIMU im. N.I. Pirogova, Moskva

Chapurin S.A.

Moskovskiĭ NII psikhiatrii;
psikhonevrologicheskiĭ dispanser #13, Moskva

Churilin Iu.Iu.

Moskovskiĭ NII psikhiatrii;
psikhonevrologicheskiĭ dispanser #13, Moskva

Lugovskikh E.A.

Kafedra infektsionnykh bolezneĭ i épidemiologii MGMSU im. A.I. Evdokimova Minzdrava Rossii;
kafedra klinicheskoĭ farmakologii lechebnogo fakul'teta RNIMU im. N.I. Pirogova, Moskva

Close metadata

References:

Yushchuk N.D., Klimova E.A., Znoiko O.O. i dr. Virusnye gepatity. Klinika, diagnostika, lechenie. M: GEOTAR-Media 2012.
Yushchuk N.D., Znoiko O.O., Yakushechkina N.A. i dr. Otsenka sotsial'no-ekonomicheskogo bremeni gepatita S v Rossiiskoi Federatsii. Epidemiol i vaktsinoprof 2013; 2: 18-33.
Bennett W.G., Inoue Y., Beck J.R. et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-865.
Wright M., Grieve R., Roberts J. et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006; 10: 1-113, iii.
Shepherd J. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-205, iii.
Kozlova A.V. Profilaktika i lechenie vozvratnykh infektsii posle ortotopicheskoi allotransplantatsii pecheni u bol'nykh tsirrozom pecheni HBV- i HCV-etiologii: Avtoref dis. ... med. nauk. M 2011.
Grishchenko M., Grieve R.D., Sweeting M.J. et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009; 25: 171-180.
Yagudina R.I., Kulikov A.Yu., Serpik V.G. Diskontirovanie pri provedenii farmakoekonomicheskikh issledovanii. Farmakoekonomika 2009; 4: 10-13.
Chepurina M.N., Kiseleva E.A. Kurs ekonomicheskoi teorii. Kirov: ASA 1999.
Breili R., Maiers S. Printsipy korporativnykh finansov: Per. s angl. M: Olimp-Biznes 1997.
Protokol diagnostiki i lecheniya bol'nykh virusnymi gepatitami V i S. Ros zhurn gastroenterol, gepatol i koloproktol 2010; 6: 4-60.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
Ivashkin V.T., Yushchuk N.D., Maevskaya M.V. i dr. Rekomendatsii po diagnostike i lecheniyu vzroslykh bol'nykh gepatitom S. RZhGGK 2013; 23 (2): 41-70.
McHutchison J.G., Lawitz E.J., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361 (6): 580-593.
Pearlman B.L., Traub N. Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More. Clin Infect Dis 2011; 52 (7): 889-900.
Bruno S., Battezzati P.M., Bellati G. et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001; 34: 748-755.
Bruno S., Stroffolini T., Colombo M. et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
Buti M., Esteban R. Long-term outcome after interferon therapy in patients with chronic hepatitis C. Ann Hepatol 2007; 6: 267-269.
Duchatelle V., Marcellin P., Giostra E. et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. J Hepatol 1998; 29: 20-28.
Thein H.H., Yi Q., Dore G.J., Krahn M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and metaregression. Hepatology 2008; 48: 418-431.
Jacobson I.M., McHutchinson J., Dusheiko G. et al. Telaprevir for previously untreated chronic Hepatitis C Virus Infection. N Engl J Med 2011; 364 (25): 2405-2416.
Zeuzem S., Rizzetto M., Ferenci P., Shiffman M.L. Management of hepatitis C virus of genotype 2 or 3 infection: treatment optimization on the basis of virological response. Antiviral Ther 2009; 14: 143-154.